American Cancer Society BrightEdge

Funding rounds backed by American Cancer Society BrightEdge.

Export CSV
Funding disclosed in full
$224.5M
Median round
$112.3M
Rounds in calculation
2
2 rounds
LatestLargest
Funding rounds with company descriptions, amounts, stages and announcement dates
CompanyRoundMarketInvestorsAnnouncedDetails
CellCentric

Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma

$220MSeries DBiotechUnited Kingdom
9 participantsAmerican Cancer Society BrightEdgeAvego BioScience CapitalFidelity Management & Research CompanyForbionHBM HealthcarePfizerRA Capital ManagementSofinnova PartnersVenrock Healthcare Capital Partners
TippingPoint Biosciences

Develops novel drug discovery platform to target epigenetic targets in pediatric brain cancer

$4.5MSeedBiotechUnited States
9 participantsAmerican Cancer Society BrightEdgeFreeflow VenturesLKS FundSazze PartnersSontag Innovation FundSOSVStoryHouse VenturesWeCANXEIA